Cipla launches India's first inhalable insulin ‘Afrezza’
Afrezza, developed by MannKind Corporation in the USA, offers a needle-free, rapid-acting insulin option for diabetes management
Afrezza, developed by MannKind Corporation in the USA, offers a needle-free, rapid-acting insulin option for diabetes management
Sitagliptin and Metformin Hydrochloride Tablets, 50 mg/500 mg and 50 mg/1000 mg are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
The GL 22 Blood Glucose Monitor combines German precision with advanced technology designed to meet local needs
Efficacy and safety from this phase IV study were consistent with data from the Vabysmo phase III DME studies
The market size of Aspart in India is currently estimated over Rs. 260 crore with only 2 players
Lyka has received the CDSCO approval for manufacturing and marketing of Pregabalin Gel 8% w/w
Strokes are affecting approximately 1.8 million people annually
Under the licensing agreement, Alkem will carry out the clinical development of “SON-080” in India with support from Sonnet and enable global and India regulatory filings
Subscribe To Our Newsletter & Stay Updated